Department of Respiratory Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
Department of Respiratory Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
Respir Investig. 2022 May;60(3):418-424. doi: 10.1016/j.resinv.2022.02.004. Epub 2022 Mar 7.
In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were included. Among these, 41 patients in the baricitinib group and 41 patients in the control group were selected by propensity score matching to adjust for background factors. We compared the survival rates of the two groups at 30 and 60 days after admission. The 30-day survival rate was significantly higher in the baricitinib group than in the control group. However, there was no significant difference in 60-day survival in the two groups. Baricitinib may improve the early prognosis of patients with respiratory failure associated with COVID-19. However, efforts should be made to improve the long-term prognosis.
在这项回顾性队列研究中，我们评估了巴瑞替尼治疗 2019 冠状病毒病（COVID-19）的疗效。在 2020 年 10 月 23 日至 2021 年 7 月 31 日期间我院收治的 404 例成年 COVID-19 患者中，有 229 例患者出现呼吸衰竭。其中，通过倾向性评分匹配选择了巴瑞替尼组的 41 例患者和对照组的 41 例患者，以调整背景因素。我们比较了两组患者入院后 30 天和 60 天的生存率。巴瑞替尼组的 30 天生存率显著高于对照组。然而，两组患者的 60 天生存率无显著差异。巴瑞替尼可能改善与 COVID-19 相关的呼吸衰竭患者的早期预后。但是，应努力改善患者的长期预后。
